Finding new drugs to target liver cancer
Official title: Discovery and validation of CYP8B1 Inhibitors as probes for targeting Hepatocellular Carcinomas (HCC)
Funded at Beckman Research Institute/city of Hope · NIH-11159259 · Data updated 2026-11-12
This study is looking for new ways to treat liver cancer by targeting a specific protein called CYP8B1, which could help improve treatments and boost the immune system's ability to fight the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | April 15, 2025 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $793,324 |
| NIH project number | 1R01CA301510-01 |
| Project ID | NIH-11159259 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hepatocellular carcinoma, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with other types of cancer or those who do not have hepatocellular carcinoma may not benefit from this research.
What this research studies
This research focuses on hepatocellular carcinoma (HCC), a severe form of liver cancer that is difficult to treat with current therapies. The team aims to discover and validate new inhibitors of the CYP8B1 protein, which plays a crucial role in liver metabolism and cancer development. By targeting CYP8B1, the research seeks to create innovative treatments that could improve patient outcomes and reduce cancer resistance. The approach involves studying the effects of these inhibitors on cancer cells and their potential to enhance the body's immune response against tumors.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with liver cancer.
How similar studies have gone: Previous research has shown promise in targeting similar metabolic pathways in cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Huang, Wendong — Beckman Research Institute/city of Hope
- Study coordinator: Huang, Wendong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.